Published in Mol Cell Biol on January 01, 2000
AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol (2001) 2.81
Targeting protein prenylation for cancer therapy. Nat Rev Cancer (2011) 2.60
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol (2004) 1.41
RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol (2000) 1.35
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer (2004) 1.31
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res (2011) 1.23
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2011) 1.19
Akt2 kinase suppresses glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-mediated apoptosis in ovarian cancer cells via phosphorylating GAPDH at threonine 237 and decreasing its nuclear translocation. J Biol Chem (2011) 1.14
The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer (2008) 1.12
Retracted A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. J Biol Chem (2010) 0.98
Downregulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia (2001) 0.97
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood (2011) 0.95
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res (2011) 0.95
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother (2009) 0.95
Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells. PLoS One (2011) 0.93
Modulation of the mevalonate pathway by akt regulates macrophage survival and development of pulmonary fibrosis. J Biol Chem (2014) 0.93
The association of ClipR-59 protein with AS160 modulates AS160 protein phosphorylation and adipocyte Glut4 protein membrane translocation. J Biol Chem (2012) 0.88
Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood (2011) 0.87
New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res (2004) 0.86
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics (2008) 0.85
Downregulation of Epidermal Growth Factor Receptor Expression Contributes to alpha-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines. J Oncol (2010) 0.85
Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer (2015) 0.85
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. J Pharmacol Exp Ther (2011) 0.83
Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Mol Cancer (2010) 0.83
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Br J Cancer (2005) 0.81
mTOR-Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1. Pharmacol Res (2016) 0.78
The Metabolic Prospective and Redox Regulation of Macrophage Polarization. J Clin Cell Immunol (2015) 0.78
Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol (2014) 0.76
Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.75
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem (1998) 17.36
Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell (1998) 13.98
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12.55
The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell (1995) 11.86
Rho GTPases and signaling networks. Genes Dev (1997) 11.70
Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 11.61
Regulation of cell death protease caspase-9 by phosphorylation. Science (1998) 11.26
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell (1996) 10.83
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages. Cell (1997) 10.22
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (1997) 9.58
Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature (1997) 8.52
Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science (1997) 8.17
Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem (1996) 8.08
Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature (1985) 7.10
Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell (1997) 6.55
A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science (1991) 6.54
Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J (1997) 6.14
Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature (1996) 6.02
Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A (1998) 5.98
Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science (1998) 5.62
An essential role for Rac in Ras transformation. Nature (1995) 5.34
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol (1995) 4.78
Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature (1997) 4.66
Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A (1991) 4.66
Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature (1993) 4.61
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev (1998) 4.22
Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell (1997) 3.90
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 3.73
Integrin signaling and cell growth control. Curr Opin Cell Biol (1998) 3.32
Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem (1996) 3.21
Focal adhesion kinase and associated proteins. Curr Opin Cell Biol (1994) 3.06
Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J Biol Chem (1997) 2.70
Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol (1997) 2.67
Integrin activation by R-ras. Cell (1996) 2.50
Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J (1998) 2.13
Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog (1998) 2.06
The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene (1993) 2.05
Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene (1998) 2.03
Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J Biol Chem (1996) 1.97
Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol (1998) 1.93
Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun (1995) 1.90
Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene (1998) 1.82
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem (1995) 1.75
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A (1998) 1.70
Molecular cloning of a second form of rac protein kinase. Cell Regul (1991) 1.63
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
The activation of p38 and apoptosis by the inhibition of Erk is antagonized by the phosphoinositide 3-kinase/Akt pathway. J Biol Chem (1998) 1.46
Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene (1997) 1.46
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta (1997) 1.42
The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J Biol Chem (1998) 1.39
Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway. Mol Cell Biol (1997) 1.39
A region of the 85-kilodalton (kDa) subunit of phosphatidylinositol 3-kinase binds the 110-kDa catalytic subunit in vivo. Mol Cell Biol (1993) 1.36
Integrin-mediated signaling events in human endothelial cells. Mol Biol Cell (1998) 1.35
Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol (1995) 1.30
Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol (1999) 1.29
Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem Biophys Res Commun (1996) 1.28
The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol (1997) 1.27
Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res (1997) 1.24
Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res (1995) 1.18
Suppression of interleukin-1 beta-converting enzyme-mediated cell death by insulin-like growth factor. J Biol Chem (1996) 1.18
Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin. J Cell Physiol (1993) 1.13
GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res (1997) 1.11
Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras. Mol Cell Biol (1998) 1.10
Protein kinase C modulates the insulin-stimulated increase in Akt1 and Akt3 activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun (1998) 0.95
Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A (1998) 0.93
Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol Ther (1997) 0.92
Translocation and activation of AKT2 in response to stimulation by insulin. J Cell Biochem (1998) 0.91
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer (1995) 5.24
Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol (1998) 3.28
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet (1999) 2.84
AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol (2001) 2.81
Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol (1994) 2.65
Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene (2000) 2.55
Abdominal wall metastases from ovarian cancer after laparoscopy. Am J Obstet Gynecol (1993) 2.16
Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res (2001) 2.10
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09
Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog (1998) 2.06
Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg (2000) 1.98
The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem (1997) 1.98
Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin. Oncogene (1998) 1.82
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene (2000) 1.80
Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene (2008) 1.76
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A (1995) 1.76
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem (1995) 1.75
Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene. Oncogene (1995) 1.67
Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. J Am Chem Soc (2001) 1.67
Peptide and protein recognition by designed molecules. Chem Rev (2000) 1.61
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Ther (2010) 1.56
High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer. Blood (1993) 1.54
Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol (1999) 1.52
Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene (1993) 1.49
The ERGB/Fli-1 gene: isolation and characterization of a new member of the family of human ETS transcription factors. Cell Growth Differ (1992) 1.49
Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene (1997) 1.48
Medical professional involvement in smartphone 'apps' in dermatology. Br J Dermatol (2012) 1.46
Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res (1994) 1.43
Analysis of residual cancer after diagnostic breast biopsy: an argument for fine-needle aspiration cytology. Ann Surg Oncol (1995) 1.42
The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem (1997) 1.35
Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem (1995) 1.33
Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg (2001) 1.31
MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol Endocrinol (2000) 1.27
Touch preparation cytology of breast lumpectomy margins with histologic correlation. Arch Surg (1991) 1.27
Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem (2000) 1.27
Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res (1994) 1.24
Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol (1994) 1.24
Public health services in Shenzhen: a case study. Public Health (2011) 1.22
Treatment of Ménétrier's disease with a monoclonal antibody against the epidermal growth factor receptor. N Engl J Med (2000) 1.20
The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ (2010) 1.20
Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res (1995) 1.18
Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat Biotechnol (2000) 1.18
Advances in the analysis of chromosome alterations in human lung carcinomas. Cancer Genet Cytogenet (1997) 1.18
p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol (1998) 1.18
Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther (2006) 1.17
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene (2007) 1.17
Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem (2001) 1.13
The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res (1996) 1.11
Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol Biol Cell (2000) 1.11
GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res (1997) 1.11
RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem (2000) 1.10
Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. J Immunol (2000) 1.10
The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem (2001) 1.10
Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients. J Urol (1996) 1.09
Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res (1998) 1.09
Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene (1996) 1.09
Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol Ther (1990) 1.08
Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem (1999) 1.08
Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem (1996) 1.07
Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol (2000) 1.07
Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma. Genes Chromosomes Cancer (1994) 1.06
Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene (2011) 1.05
Cortical granule distribution and cell surface characteristics in mouse eggs. Dev Biol (1977) 1.05
Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim (2001) 1.05
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene (2006) 1.05
Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem (1999) 1.04